- Home
- TACT vs ALGS Comparison
TACT vs ALGS Comparison
Compare TACT & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- ALGS
- Stock Information
- Founded
- TACT 1996
- ALGS 2018
- Country
- TACT United States
- ALGS United States
- Employees
- TACT N/A
- ALGS N/A
- Industry
- TACT Computer peripheral equipment
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- TACT Technology
- ALGS Health Care
- Exchange
- TACT Nasdaq
- ALGS Nasdaq
- Market Cap
- TACT 51.0M
- ALGS 53.0M
- IPO Year
- TACT 1996
- ALGS 2020
- Fundamental
- Price
- TACT $5.42
- ALGS $9.86
- Analyst Decision
- TACT Strong Buy
- ALGS Strong Buy
- Analyst Count
- TACT 1
- ALGS 2
- Target Price
- TACT $5.00
- ALGS $60.00
- AVG Volume (30 Days)
- TACT 69.2K
- ALGS 72.0K
- Earning Date
- TACT 11-06-2025
- ALGS 11-05-2025
- Dividend Yield
- TACT N/A
- ALGS N/A
- EPS Growth
- TACT N/A
- ALGS N/A
- EPS
- TACT N/A
- ALGS N/A
- Revenue
- TACT $47,949,000.00
- ALGS $3,174,000.00
- Revenue This Year
- TACT $21.67
- ALGS N/A
- Revenue Next Year
- TACT $7.63
- ALGS N/A
- P/E Ratio
- TACT N/A
- ALGS N/A
- Revenue Growth
- TACT N/A
- ALGS N/A
- 52 Week Low
- TACT $3.12
- ALGS $3.76
- 52 Week High
- TACT $5.70
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- TACT 63.38
- ALGS 50.65
- Support Level
- TACT $5.05
- ALGS $9.60
- Resistance Level
- TACT $5.70
- ALGS $10.70
- Average True Range (ATR)
- TACT 0.26
- ALGS 0.76
- MACD
- TACT -0.00
- ALGS -0.02
- Stochastic Oscillator
- TACT 74.59
- ALGS 41.30
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.